LEADER 04802nam 2200649Ia 450 001 9911019999603321 005 20200520144314.0 010 $a1-283-83537-1 010 $a3-527-63389-8 010 $a3-527-63388-X 035 $a(CKB)3400000000000401 035 $a(EBL)661793 035 $a(OCoLC)768731436 035 $a(SSID)ssj0000507243 035 $a(PQKBManifestationID)11303294 035 $a(PQKBTitleCode)TC0000507243 035 $a(PQKBWorkID)10545717 035 $a(PQKB)11256023 035 $a(MiAaPQ)EBC661793 035 $a(EXLCZ)993400000000000401 100 $a20110808d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aApicomplexan parasites $emolecular approaches toward targeted drug development /$fedited by Katja Becker 205 $a4th ed. 210 $aWeinheim $cWiley-Blackwell$dc2011 215 $a1 online resource (552 p.) 225 1 $aDrug discovery in infectious diseases ;$vv. 2 300 $aDescription based upon print version of record. 311 $a3-527-32731-2 320 $aIncludes bibliographical references and index. 327 $aApicomplexan Parasites: Molecular Approaches toward Targeted Drug Development; Foreword; Contents; Preface; List of Contributors; Part One: Screening, Bioinformatics, Chemoinformatics, and Drug Design; 1 Drug Discovery Approaches Toward Anti-Parasitic Agents; 2 New Bioinformatic Strategies Against Apicomplexan Parasites; 3 Sorting Potential Therapeutic Targets in Apicomplexa; 4 Alternatives to Drug Development in the Apicomplexa; Part Two: Metabolic Pathways and Processes Addressed by Current Drug Discovery Approaches; 5 Energy Metabolism as an Antimalarial Drug Target 327 $a6 Polyamines in Apicomplexan Parasites7 The Reducing Milieu of Parasitized Cells as a Target of Antimalarial Agents: Methylene Blue as an Ethical Drug; 8 Lipids as Drug Targets for Malaria Therapy; 9 Targeting Apicoplast Pathways in Plasmodium; 10 Lipoic Acid Acquisition and Glutathione Biosynthesis in Apicomplexan Parasites; 11 Antimalarial Drugs and Molecules Inhibiting Hemozoin Formation; 12 Exploiting the Vitamin Metabolism of Apicomplexa as Drug Targets; 13 Vitamin Biosynthetic Pathways, the PLP Synthase Complex, and the Potential for Targeting Protein-Protein Interaction 327 $a14 Targeting Prokaryotic Enzymes in the Eukaryotic Pathogen CryptosporidiumPart Three: Drug Targets in Apicomplexan Parasites; 15 Novel Apicomplexan Phosphatases and Immunophilins as Domain-Specific Drug Targets; 16 Dehydrogenases and Enzymes of the Mitochondrial Electron Transport Chain as Anti-Apicomplexan Drug Targets; 17 Calcium-Dependent Protein Kinases as Drug Targets in Apicomplexan Parasites; 18 Protein Acylation: New Potential Targets for Intervention Against the Apicomplexa; 19 Drugs and Drug Targets in Neospora caninum and Related Apicomplexans; Part Four: Compounds 327 $a20 Subversive Substrates of Glutathione Reductases from Plasmodium falciparum-Infected Red Blood Cells as Antimalarial Agents21 Ferroquine: A Concealed Weapon; 22 Current Aspects of Endoperoxides in Antiparasitic Chemotherapy; 23 Plasmodium Hsp90 as an Antimalarial Target; 24 Drug Discovery Against Babesia and Toxoplasma; 25 Search for Drugs and Drug Targets against Babesia bovis, Babesia bigemina, Babesia caballi, and Babesia (Theileria) equi; 26 Orlistat: A Repositioning Opportunity as a Growth Inhibitor of Apicomplexan Parasites?; 27 Recent Drug Discovery Against Cryptosporidium; Index 330 $aThis handbook is the first dealing with the discovery of drugs directed against apicomplexan parasites. Amongst others, this group of endoparasites includes the causative agents of Malaria, Toxoplasmosis, and Babesiosis, the latter occurring mainly in animals. Written by renowned scientific experts from academia and industry, the book focuses on currentdrug development approaches for all apicomplexan diseases making it appealing to a large audience, ranging from research labs in academia to the human and veterinarian pharmaceutical industry. This work is the second volume of the new book seri 410 0$aDrug discovery in infectious diseases ;$vv. 2. 606 $aAntiprotozoal agents 606 $aProtozoan diseases$xChemotherapy 606 $aApicomplexa 606 $aDrug development 615 0$aAntiprotozoal agents. 615 0$aProtozoan diseases$xChemotherapy. 615 0$aApicomplexa. 615 0$aDrug development. 676 $a616.9/6 701 $aBecker$b Katja$f1965-$01838885 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911019999603321 996 $aApicomplexan parasites$94417972 997 $aUNINA